2017 ASCO Annual Meeting

June 5, 2017

Title: A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.

Date: Monday, June 5, 2017

Time: 8:00 AM - 11:30 AM

Location: Hall A

Poster Board #: 191A



Email Address: *
First Name:
Mailing Lists

Enter the code shown above.

Powered By Q4 Inc.